Pharma/Fine Chemicals Roundup – September 11
11:17 AM MDT | September 11, 2012 | By DEEPTI RAMESH
CAMBRIDGE MAJOR EXPANDS API FACILITY
Cambridge Major Laboratories (CML; Germantown, WI) says it has significantly expanded its active pharmaceutical ingredient (API) manufacturing facility at Germantown, following continued growth in demand for larger-scale API manufacturing services. Details of the production capacity were not disclosed. The expansion includes significant additional reactor capacity as well as isolation equipment; the company has also made additional investments in engineering controls to ensure the sustainability of the business, CML says.
HOVIONE APPOINTS GM AT TECHNOLOGY TRANSFER CENTER IN U.S.
Active pharmaceutical ingredients (API) manufacturer Hovione (Loures, Portugal) has appointed Mike Ironside as general manager at its technology transfer center in New Jersey. Mike Ironside was previously with GSK in the U.K.; as well as with two companies in U.S.: AMRI and, most recently, Anacor Pharmaceuticals, where he held the position of v.p./chemical manufacture and development. Mike Ironside brings over 20 years of experience in the development and scale-up of APIs from lead candidate optimization through to new drug application submission and commercialization, Hovione says. Mike Ironside’s experience in “chemical and analytical process development, scale-up from pilot plant to full commercial-scale, will enable us to further strengthen and enlarge our U.S. operations in New Jersey and add new approaches to solve our customers’ most challenging problems,” says Thomas Eisele, v.p./corporate research & development.
MYLAN’S INDIAN API SUBSIDIARY SELECTED AS SUPPLIER TO INDIA'S AIDS CONTROL ORGANIZATION
Mylan (Canonsburg, PA) says that its Mylan Laboratories (Hyderabad, India) subsidiary has been selected as a leading supplier of antiretroviral (ARV) drugs to the Indian government's National AIDS Control Organisation (NACO; New Delhi). Mylan Laboratories is one of the world’s largest manufacturers of active pharmaceutical ingredients (APIs), and the company also maintains a portfolio of finished dosage forms of generic ARV drugs. Mylan's range of ARV products includes APIs and 43 first- and second-line finished doses, nine of which are pediatric products. NACO is responsible for overseeing HIV/AIDS control programs in India. NACO's objective is to halt and reverse the HIV/AIDS epidemic in India over the next five years through integrated programs for prevention, care and support, and treatment. NACO manages 35 HIV prevention and control societies, which implement NACO's programs at the state level and manage more than 350 ARV treatment centers, Mylan says.
AMRI APPOINTS NEW SENIOR DIRECTOR OF BUSINESS DEVELOPMENT
Albany Molecular Research (AMRI; Albany, NY) says that Daniel Conlon has been promoted to senior director/business development, and will report to Christopher Conway, v.p./business development, North America. In the newly created role, Conlon will lead AMRI's development and manufacturing services sales team for North America. His responsibilities will include assisting with the strategic direction for generating sales in the North American territory and with the execution of revenue goals for his team.
TAKEDA BUILDS RUSSIAN PHARMA FACILITY
Takeda Pharmaceuticals International (Zurich), a subsidiary of Takeda Pharmaceutical (Osaka) says it has completed the construction of its pharmaceutical manufacturing facility at Yaroslavl, Russia. Takeda invested about €75 million ($96.48 million) in the production plant, which is expected to be fully operational by 2014. The plant will supply tablet and sterile liquid products to the local market. “Russia is our largest emerging market in terms of revenues, and is expected to contribute significantly to our growth over the next few years,” says Yasuchika Hasegawa, president and CEO of Takeda.
BAYER HEALTHCARE OPENS LIFE SCIENCES HUB FOR RESEARCH COMPANIES
Bayer HealthCare, a subgroup of Bayer, has opened its new life sciences hub for early-stage research companies, CoLaborator, at San Francisco, CA. The hub will support start-ups in establishing their research labs. In addition to lab facilities, access to the global expertise and equipment of Bayer’s research network will be available to CoLaborator scientists. In return for ready-to-use lab space and access to its global expertise, Bayer will seek preferred access to partner with the emerging companies. The CoLaborator life sciences hub is adjacent to Bayer HealthCare’s U.S. Innovation Center and seeks to work with technology platforms, drug targets, or drug candidates that align with Bayer’s research strategy.
Connect with IHS Chemical Week
Our related sites